

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

1st August, 2023

Corporate Relationship Department M/s. BSE Limited Dalal Street, Fort **Mumbai 400 001**.

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex **Bandra (E)** Mumbai 400 051.

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Q1FY24 Financial Results Earnings Call

The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on Thursday, 10th August, 2023 to disseminate Financial Results of the Company for the quarter ended on 30th June, 2023.

Copy of the same is enclosed for your ready reference.

Thanking you,

Yours faithfully, For NATCO Pharma Limited

Chekuri Venkat Ramesh Company Secretary & Compliance Officer

NATCO PHARMA



Hosted by Nuvama Institutional Equities

India Equity Research August 1, 2023

We are organising a conference call with the management of Natco Pharma to discuss the Company's Q1FY24 financial results on Thursday, August 10, 2023 at 11.00 AM IST.

Mr. Rajeev Nannapaneni, Director & Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President – Crop Health Sciences will represent Natco Pharma on the call.

Details of the conference call are as under:

Time : 11.00 AM IST on Thursday, August 10, 2023

Conference dial-in:			
India	:	Mumbai	
	:	Primary access number	+ 91 22 6280 1560
			+91 22 7115 8200
USA	:		1 866 746 2133
UK	:		0 808 101 1573
Singapore Toll Free No.			800 101 2045
Hong Kong Toll Free No.	:		800 964 448

Call leader Mr. Kunal Randeria

For further information, please contact:

Kunal Randeria

Director - Research, Nuvama Institutional Equities

Tel.: +91 6620 3040

E-mail: kunal.randeria@nuvama.com

Express Join with **DiamondPass™**